I. F. Quijorna

Characterization of an immune-evading doxycycline-inducible lentiviral vector for gene therapy in the spinal cord

J. Verhaagen, R. Eggers, B. Hobo, 2022, Experimental Neurology.

Activation of inflammatory resolution programs as a new therapeutic approach to promote neuroprotectin after SCI

I. F. Quijorna, 2016 .

Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines

M. Malim, A. Hayday, S. Irshad, 2021, medRxiv.